### Supplementary material

### 1. Method

1

2

3

12

13

14

15

16

17

18

19

20

21

# 1.1 Synthesis of Cy7-labeled COS (COS-Cy7)

Synthesis was performed as previously described with some minor 4 modifications[1]. COS (100 mg) was dissolved in 8 mL distilled water; the pH of the 5 6 reaction solution was adjusted to 9.0 (using 0.5 M NaOH). Cy7-NHS ester (1 mg/mL) 7 initially dissolved in 1 mL distilled water was added to a stirred solution of COS. The 8 reaction mixture was stirred magnetically for 12 h (in the dark) at room temperature. 9 The obtained mixture was lyophilized and then washed with 5 mL DMSO. After every 10 run of wash, the mixture was centrifuged (for 10 min at 10000 rpm) to remove the 11 unreacted Cy7-NHS; washing repeated 10 times. Finally, the purified COS-Cy7 was

reconstituted in approximately 200 µL distilled water and lyophilized.

## 1.2 Physiochemical characterization

COS-Cy7 (0.1 μg/mL) was analyzed by Time-of-Flight-Mass Spectrometer (TOF6600-MS4500, Agilent, USA). Briefly, COS-Cy7 powder was dissolved in distilled water, and a small aliquot (1 mL) was used for analysis by TOF-MS. The mobile phase was a mixture of methanol and distilled water (80/20, *v/v*). To verify the chemical structure of COS and COS-Cy7, Fourier transforms infrared spectroscopy (FT-IR) spectra were recorded on a PerkinElmer Spectrum<sup>TM</sup> (Specrum 100). KBr method was adopted for testing sample preparation. The absorption and fluorescence spectra of COS-Cy7 and Cy7-NHS were recorded with Infinite M200 microplate reader

22 (TECAN, Switzerland).

#### 2. Results

23

24

# 2.1 Synthesis and characterization of COS-Cy7

25 COS used in the present study was analyzed as previously reported [2]. COS-Cy7 26 was synthesized via a one-step protocol (Fig. S1). COS was labeled with Cy7-NHS 27 ester by acylating their primary amines. COS-Cy7 was obtained as a solid powder after freeze-drying. The chemical structures of COS and COS-Cy7 were characterized by 28 29 FT-IR. The FT-IR spectra of COS (Fig. S2A) showed basic characteristic absorption 30 peaks at 1080 cm<sup>-1</sup> (C-O stretching vibration of 3-OH) and 1623 cm<sup>-1</sup> (-NH2). On the other hand, the characteristic band at 1623 cm<sup>-1</sup> was disappeared in the FT-IR spectrum 31 32 of COS-Cy7 (Fig. S2A), indicating amidation of NH<sub>2</sub> of COS. Furthermore, multiple 33 characteristic peaks at approximately 2400 cm<sup>-1</sup> (attributed to N-H stretching vibration in secondary amine) revealed the acylation of COS. Peaks higher than 1000 in TOF-34 35 MS results also confirmed the synthesis of COS-Cy7 (Fig. S3). 36 UV-vis spectrum analysis showed that COS-Cy7 had an absorbance peak at a 37 wavelength of 748 nm and conjugated ~1.2 nmol of Cy7 per 1 mg of COS (Fig. S2B). 38 COS-Cy7 and Cy7-NHS almost have the same pattern of UV-vis. This is because that 39 both of them have the same fluorescence emission and excitation spectrum, as measured 40 by fluorescence spectrophotometer (Fig. S2C and S2D). These results imply that chemical conjugation of Cy7 to COS does not affect the emission and excitation 41 42 spectrum of Cy7-NHS.

Fig. S1 Synthesis formula of COS-Cy7




Fig.S2 Characterization of COS-Cy7. (A) FT-IR spectra of COS and COS-Cy7. (B) UV-vis spectrum of COS-Cy7. (C) Fluorescence spectrum of COS-Cy7 and Cy7-NHS at an excitation wavelength of 725 nm. (D) Fluorescence spectrum of COS-Cy7 and Cy7-NHS at an emission wavelength of 795 nm




Fig. S3 MALDI-TOF-MS image of COS-Cy7

Project	Standards
Appearance	Off white powder
Deacetylation	≥90%
рН	7-8
Loss on drying	≤8%
Ignition Residue	≤0.5%
Undissolved Substance	≤1%
Particle Size	200 mpa.s
Heavy Metal	≤10 ppm
Arsenic	≤0.5 ppm
Particle Size	40-100 mesh
Yeast & Mould	$\leq 10 \text{ cfu/g}$
<b>Total Plate Counts</b>	$\leq 1000 \text{ cfu/g}$

Table S2 Primers used for qRT-PCR.

Gene names	Primers
β-actin	Forward 5'-GAAGATCAAGATCATTGCTCCTC-3'
	Reverse 5'-ATCCACATCTGCTGGAAGG-3'
HMOX1	Forward 5'-GAACTTTCAGAAGGGCCAG-3'
	Reverse 5'-TAGATGTGGTACAGGGAGG-3'
GCLM	Forward 5'-GTTGACATGGCCTGTTCAG-3'
	Reverse 5'-AACTCCATCTTCAATAGGAGGT-3'
SLC7A11	Forward 5'-CATCGTCCTTTCAAGGTGC-3'
	Reverse 5'-ATAGAGGGAAAGGGCAACC-3'
Nrf2	Forward 5'-AGGTTGCCCACATTCCCAAA-3'
	Reverse 5'-ACGTAGCCGAAGAAACCTCA-3'

Table S3 Flow cytometry analysis of KCC853 after COS treatment.

Group	Apoptosis state (%)				Cell cycle distribution (%)				
	Live	Early		Late		Dead	G0/G1	G2/M	S
		apoptosis		apoptosis					
Control	91.15	2.52	$\pm$	3.34	$\pm$	$3.00 \pm$	67.91 ±	$8.76 \pm$	23.32
	$\pm 0.04$	0.34		0.06		0.36	5.61	1.62	$\pm 2.48$
COS-	91.30	3.33	$\pm$	4.15	$\pm$	$1.23 \pm$	$68.70\pm$	$9.18 \pm$	22.12
250	$\pm 0.28$	0.52		0.19		0.05	3.12	0.65	$\pm 1.06$
COS-	83.81	6.96	$\pm$	7.70	$\pm$	$1.55 \pm$	$64.40 \pm$	$7.42 \pm$	28.14
500	$\pm 0.64$	0.11		0.49		0.05	4.50	1.97	$\pm 2.35$
COS-	26.77	55.05	$\pm$	15.11	$\pm$	$3.07 \pm$	$43.07\pm$	25.35	31.58
1000	$\pm 0.21$	0.91		0.27		0.96	2.67	$\pm 1.66$	$\pm 2.11$

Table S4 Biomarkers in serum of liver and kidney function of mice that received the different treatment.

different treatment.						
	BUN	Cr	AKP	ALT	AST	ALB
	8.73±1.6	11.25±4.1	57.13±11.7		138.38±25.8	24.83±1.5
Control	3	3	6	35.13±7.92	8	7
COS	$6.86 \pm 0.9$	$10.38 \pm 1.1$	$65.13\pm17.2$	$37.25\pm12.0$	121.13±29.0	$26.48\pm2.1$
10	4	9	6	7	2	0
COS	$8.97 \pm 0.9$	12.29±0.9	$62.00\pm19.3$	43.00±18.7	168.43±35.2	$25.66 \pm 1.0$
20	4	5	2	3	4	7
COS	8.67±1.6		$65.00\pm15.5$	$38.17\pm22.5$	105.67±25.9	$27.32\pm1.2$
40	6	9.67±1.63	8	9	0	2

## References

[1] Li, J., Jiang, B., Lin, C., Zhuang, Z., Fluorescence tomographic imaging of sentinel lymph node using near-infrared emitting bioreducible dextran nanogels. *International Journal of Nanomedicine* 2014, *9*, 5667-5682.

[2] Zhai, X., Yang, X., Zou, P., Shao, Y., *et al.*, Protective Effect of Chitosan Oligosaccharides Against Cyclophosphamide-Induced Immunosuppression and Irradiation Injury in Mice. *Journal of food science* 2018, *83*, 535-542.